Posts

FDA APPROVES ZELBORAF AND COMPANION DIAGNOSTIC TEST FOR LATE-STAGE SKIN CANCER

ADCETRIS TO TREAT TWO TYPES OF LYMPHOMA

FDA ISSUES NEW GUIDELINES TO IMPROVE QUALITY OF CLINICAL TRIAL

CARDIAC MYOSIN ACTIVATORS: A NEW CLASS OF DRUGS FOR HEART FAILURE TREATMENT

PFIZER CONDUCTS FIRST “VIRTUAL” CLINICAL TRIAL

RECENT MEDICAL DEVICE RECALLS BY FDA

FDA APPROVES GADAVIST AS IMAGING AGENT FOR CENTRAL NERVOUS SYSTEM SCANS

SAREUM REPORT POSITIVE TESTS ON CANCER DRUGS

FDA APPROVES NEW DRUG TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE

FDA APPROVES EDARBI TO TREAT HIGH BLOOD PRESSURE

BOTOX EFFECTIVE IN VAGINAL SPASM

INDIA HIV VACCINE UNDERGOES FIRST PHASE OF CLINICAL TRIAL

IMMUPHARMA UPDATES ON CANCER COMPOUND PHASE I/IIA CLINICAL TRIAL

JOHNSON & JOHNSON UNIT RECALLS 70,000 SYRINGES OF ANTIPSYCHOTIC DRUG INVEGA DUE TO CRACKS

ANTIPSYCHOTIC DRUG LABELS UPDATED ON USE DURING PREGNANCY AND RISK OF ABNORMAL MUSCLE MOVEMENTS AND WITHDRAWAL SYMPTOMS IN NEWBORNS

FDA DRUG SAFETY COMMUNICATION: NEW WARNINGS AGAINST USE OF TERBUTALINE TO TREAT PRETERM LABOR

MEDICAL EXPERTS ISSUE WARNING ABOUT COMMON PRACTICE OF TABLET SPLITTING

FDA LIMITS ACETAMINOPHEN IN PRESCRIPTION COMBINATION PRODUCTS; REQUIRES LIVER TOXICITY WARNINGS

FDA DRUG SAFETY COMMUNICATION: SEVERE LIVER INJURY ASSOCIATED WITH THE USE OF DRONEDARONE (MARKETED AS MULTAQ)